GLP-1 weight-loss drugs offer promising results but come with potential risks and unknown long-term effects, emphasizing the ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...

There’s no denying the popularity of weight-loss drugs in the United States, with one in eight adults relying on GLP-1s to ...

Thousands of patients are suing over alleged GLP-1 drug injuries. Drugs include Ozempic, Wegovy and Mounjaro.

Lawsuits continue against makers of GLP-1 weight-loss drugs over side effects ranging from extreme vomiting to what some plaintiffs describe as “eye strokes,” according to multiple media reports.

As many as 12% of Americans are currently using GLP-1 medications such as Ozempic and Wegovy, according to one estimate.

GLP-1 drugs might lead people to shun alcohol entirely: or the effect may be more nuanced. People might have one drink to ...

The desire for smaller portions and fewer junk foods is affecting what the food industry is selling us.

A cohort study of liver transplant candidates with HCC suggested that local-regional therapy with yttrium-90 transarterial ...

Poison control calls involving GLP-1 medications like semaglutide and tirzepatide have dramatically risen in recent years.

Association driven by fewer major amputations ...